We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+7.07%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$7.57B
AUM Growth
+$643M
Cap. Flow
+$235M
Cap. Flow %
3.1%
Top 10 Hldgs %
16.13%
Holding
1,154
New
305
Increased
228
Reduced
235
Closed
370

Top Buys

Rank Stock Value
1
AGN
Allergan Inc
AGN
+$71M
2
BAX icon
Baxter International
BAX
+$60.7M
3
TMUS icon
T-Mobile US
TMUS
+$60.1M
4
PRGO icon
Perrigo
PRGO
+$53.7M
5
NRG icon
NRG Energy
NRG
+$50.9M

Sector Composition

Rank Sector Weight
1 Healthcare 18.11%
2 Industrials 11.84%
3 Consumer Discretionary 11.65%
4 Technology 10.61%
5 Financials 10.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ANDV
101
DELISTED
Andeavor
ANDV
$20.4M 0.27%
+274,734
New +$19.4M
CBOE icon
102
Cboe Global Markets
CBOE
$30.1B
$20.4M 0.27%
321,106
+79,476
+33% +$4.74M
CTSH icon
103
Cognizant
CTSH
$25.3B
$20M 0.26%
380,731
+344,938
+964% +$17.2M
NVS icon
104
Novartis
NVS
$291B
$20M 0.26%
+240,741
New +$20M
SEE
105
DELISTED
Sealed Air
SEE
$19.9M 0.26%
468,391
-49,305
-10% -$1.85M
CASY icon
106
Casey's General Stores
CASY
$31.5B
$19.1M 0.25%
211,108
+65,499
+45% +$5.37M
MA icon
107
Mastercard
MA
$500B
$18.9M 0.25%
219,235
+161,379
+279% +$13.2M
WDR
108
DELISTED
Waddell & Reed Financial, Inc.
WDR
$18.9M 0.25%
378,839
+121,831
+47% +$5.81M
BIDU icon
109
Baidu
BIDU
$38.2B
$18.7M 0.25%
81,897
-27,914
-25% -$6.4M
ATVI
110
DELISTED
Activision Blizzard
ATVI
$18.6M 0.25%
925,088
+811,776
+716% +$16.4M
POT
111
DELISTED
Potash Corp Of Saskatchewan
POT
$18.6M 0.25%
+526,455
New +$17.9M
LII icon
112
Lennox International
LII
$15.4B
$18.2M 0.24%
+191,662
New +$17M
ADBE icon
113
Adobe
ADBE
$102B
$18M 0.24%
+248,207
New +$17.4M
BWA icon
114
BorgWarner
BWA
$12.9B
$17.9M 0.24%
369,620
+350,191
+1,802% +$17.1M
DVN icon
115
Devon Energy
DVN
$50.8B
$17.9M 0.24%
292,011
+267,472
+1,090% +$16.2M
ESNT icon
116
Essent Group
ESNT
$6.14B
$17.5M 0.23%
+681,281
New +$16.2M
MRK icon
117
Merck
MRK
$316B
$17.4M 0.23%
320,692
-158,125
-33% -$8.81M
IQV icon
118
IQVIA
IQV
$37.6B
$17.3M 0.23%
293,313
+253,617
+639% +$14.5M
LYB icon
119
LyondellBasell Industries
LYB
$19.7B
$17.2M 0.23%
216,716
+198,243
+1,073% +$17.2M
CDW icon
120
CDW
CDW
$19.7B
$17.1M 0.23%
486,151
-1,090,693
-69% -$35.3M
LLY icon
121
Eli Lilly
LLY
$995B
$16.9M 0.22%
245,452
+78,958
+47% +$5.33M
CRTO icon
122
Criteo S.A. Ordinary Shares
CRTO
$1.13B
$16.9M 0.22%
418,268
+101,150
+32% +$3.61M
AXP icon
123
American Express
AXP
$234B
$16.8M 0.22%
180,165
-207,697
-54% -$18.6M
CMA
124
DELISTED
Comerica
CMA
$16.7M 0.22%
356,757
+6,856
+2% +$322K
RRC icon
125
Range Resources
RRC
$9.28B
$16.6M 0.22%
309,880
+281,449
+990% +$18.2M

Similar funds

Marshall Wace's Q4 2014 Portfolio in Review

As of Q4 2014, Marshall Wace held 1,154 positions worth $7.57B, up 9.3% from $6.93B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Marshall Wace deployed $235M of net new capital in Q4 2014, opening 305 new positions and adding to 228 existing holdings. Its largest new stake was Baxter International: 1,557,838 shares worth $62M.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Industrials and Consumer Discretionary.

On the sell side, the largest reduction was Alibaba, an estimated $68.2M trimmed.

  • Marshall Wace's largest Q4 2014 buy was Baxter International: 1,557,838 shares worth $62M.
  • Marshall Wace added most to Allergan Inc in Q4 2014, an estimated $71M increase.
  • Marshall Wace's biggest Q4 2014 reduction was Alibaba, cutting an estimated $68.2M.
  • Marshall Wace fully exited Baker Hughes in Q4 2014, selling an estimated $40.5M.
  • Marshall Wace's ten largest holdings make up 16% of its $7.57B portfolio in Q4 2014.
  • Marshall Wace opened 305 new positions and closed 370 in Q4 2014.
  • Marshall Wace's portfolio value rose 9.3% quarter-over-quarter to $7.57B.

Based on Marshall Wace's 13F filing for Q4 2014, filed 17 Feb 2015.